The US Court of Appeals for the Federal Circuit ruled in May that the key patents on what many consider the defining biotechnology invention of the 21st century should be reconsidered. Jennifer Doudna and Emmanuelle Charpentier shared a 2020 Nobel Prize for developing the versatile gene-editing system CRISPR; however, the key patent rights were granted Feng Zhang of the Broad Institute of MIT and Harvard in 2014. The rights have been contested since, and the appeals court ruling officially opens the question of ownership anew. Our intellectual property expert, Professor Jacob Sherkow, was quoted in multiple outlets about the dispute and what it means.
Read more from Bloomberg and from the MIT Technology Review.